Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Effect of transforming growth factor-beta1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines.

Fukuda M, Ikuta K, Yanagihara K, Tajima M, Kuratsune H, Kurata T, Sairenji T.

Virology. 2001 Sep 15;288(1):109-18.

3.

Productive infection of Epstein-Barr virus (EBV) in EBV-genome-positive epithelial cell lines (GT38 and GT39) derived from gastric tissues.

Takasaka N, Tajima M, Okinaga K, Satoh Y, Hoshikawa Y, Katsumoto T, Kurata T, Sairenji T.

Virology. 1998 Aug 1;247(2):152-9.

4.

The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.

Hergenhahn M, Soto U, Weninger A, Polack A, Hsu CH, Cheng AL, Rösl F.

Mol Carcinog. 2002 Mar;33(3):137-45.

PMID:
11870879
5.

Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.

Hsu CH, Hergenhahn M, Chuang SE, Yeh PY, Wu TC, Gao M, Cheng AL.

Anticancer Res. 2002 Nov-Dec;22(6C):4065-71.

PMID:
12553034
6.

Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins.

Liang CL, Chen JL, Hsu YP, Ou JT, Chang YS.

J Biol Chem. 2002 Jun 28;277(26):23345-57. Epub 2002 Apr 23.

8.

Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.

Venkatasubbarao K, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower WR Jr, Salhab KF, McGrath P, Strodel W, Freeman JW.

Anticancer Res. 2000 Jan-Feb;20(1A):43-51.

PMID:
10769633
10.

Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.

Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP, Danielpour D, Wakefield LM.

Cancer Res. 1999 Oct 1;59(19):4834-42.

11.

Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients.

Nagata Y, Inoue H, Yamada K, Higashiyama H, Mishima K, Kizu Y, Takeda I, Mizuno F, Hayashi Y, Saito I.

Immunology. 2004 Feb;111(2):223-9.

12.

TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.

Paterson IC, Davies M, Stone A, Huntley S, Smith E, Pring M, Eveson JW, Robinson CM, Parkinson EK, Prime SS.

Oncogene. 2002 Feb 28;21(10):1616-24.

13.

DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells.

de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ.

Oncogene. 1997 Apr 24;14(16):1891-9.

14.

Nitric oxide down-regulates Epstein-Barr virus reactivation in epithelial cell lines.

Gao X, Tajima M, Sairenji T.

Virology. 1999 Jun 5;258(2):375-81.

15.

Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression.

Jong HS, Lee HS, Kim TY, Im YH, Park JW, Kim NK, Bang YJ.

Biochem Biophys Res Commun. 2002 Mar 29;292(2):383-9.

PMID:
11906173
16.

Potential role of transforming growth factor beta1 in drug resistance of tumor cells.

Stoika R, Yakymovych M, Souchelnytskyi S, Yakymovych I.

Acta Biochim Pol. 2003;50(2):497-508.

17.

Hepatitis B virus X protein promotes proliferation and upregulates TGF-beta1 and CTGF in human hepatic stellate cell line, LX-2.

Guo GH, Tan DM, Zhu PA, Liu F.

Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):59-64.

PMID:
19208517
19.

Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells.

Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK.

Am J Physiol Cell Physiol. 2004 Dec;287(6):C1560-8. Epub 2004 Aug 11.

Supplemental Content

Support Center